Skip to content
lifestyle.tweeternet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
RenovoRx, Inc.
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
March 26, 2026
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
March 23, 2026
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
March 20, 2026
RenovoRx Announces $10 Million at Market Private Placement
March 18, 2026
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
February 27, 2026
RenovoRx Establishes RenovoCath® Medical Advisory Board
February 12, 2026
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
February 11, 2026
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
February 10, 2026
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
January 20, 2026
←
Previous Page
1
2